US Pharma MarketingAs Lilly completes its pivotal program for its “triple-G” drug, Phase 1 data from Kailera partner Hengrui suggest their drug might spur greater weight loss.
Kailera’s three-pronged obesity shot shows promise in early trial
As Lilly completes its pivotal program for its “triple-G” drug, Phase 1 data from Kailera partner Hengrui suggest their drug might spur greater weight loss.
Source: BioPharma Dive